Logo

BMS's Zeposia (ozanimod) Receives the CHMP's Positive Opinion to Treat Adults with Relapsing-Remitting Multiple Sclerosis with Active Disease

Share this

BMS's Zeposia (ozanimod) Receives the CHMP's Positive Opinion to Treat Adults with Relapsing-Remitting Multiple Sclerosis with Active Disease

Shots:

  • The approval is based on P-III SUNBEAM & RADIANCE Part B studies assessing Zeposia (0.92 mg and 0.46 mg- equivalent to 1 mg and 0.5 mg ozanimod HCI) vs Avonex (qw- IM) in 1-346 & 1-320 patients with RMS for at least 12 & 24mos. treatment period respectively
  • The results will further be reviewed by the European Commission- which has the authority to approve medicines for the European Union
  • Zeposia (ozanimod) is an oral S1P receptor modulator involved in binding with S1P receptors 1 and 5. On Mar 25- 2020 the US FDA approved Zeposia for the treatment of adults with relapsing forms of multiple sclerosis (RMS)

Click here ­to­ read full press release/ article 

Ref: BMS | Image: BMS


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions